Haley Bavasi is a partner in the Seattle office of Wilson Sonsini Goodrich & Rosati, where she focuses primarily on advising digital health companies across a range of privacy, transactional, research, and healthcare regulatory issues.  In particular, Haley leverages her expertise in the Health Insurance Portability and Accountability Act (HIPAA), the U.S. federal health-privacy law, to provide early-stage companies with practical day-to-day counseling, as well advise as in the context of complex commercial transactions, M&A, and go-to-market strategy.  Haley’s extensive experience with a wide range of cutting-edge digital health companies provides her with valuable market insights she leverages for her clients.

Farah focuses on the representation of pharmaceutical, biotechnology, medical device, and diagnostic companies in complex collaboration and partnering transactions.

James advises life sciences and tech companies on a wide variety of matters and has extensive experience working with venture capital firms and other investors in private equity and debt financings.

Mark is a corporate law veteran, having advised start-ups and mature public companies for more than 25 years.

Katharine (Kathy) Ku is the chief licensing advisor in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. She is also a member of the technology transactions and the patents and innovations practice groups.

Dr. Jonathan Soderstrom is a chief licensing advisor in the New York office of Wilson Sonsini Goodrich & Rosati. He is also a member of the technology transactions and the patents and innovations practice groups. Jon has spent over 40 years managing the commercialization of intellectual property created at major public and private research institutions.

Under Jon’s leadership for 25-plus years, Yale Ventures (formerly known as Yale’s Office of Cooperative Research) helped form over 75 new ventures including Achillion Pharmaceuticals, Arvinas, NextCure, Biohaven Pharmaceuticals, and Inozyme Pharma, which have collectively raised over $1 billion in professional venture capital.

Eric Hsu is a corporate and securities partner in the life sciences practice at Wilson Sonsini Goodrich & Rosati. He represents emerging growth companies in areas such as medical devices, digital health, and biotechnology. Eric advises public and private companies on general corporate matters, mergers and acquisitions, initial public offerings, public company reporting, strategic partnerships, venture capital financings, and private equity and debt financings.

A recognized leader in his field, John specializes in in trademark, copyright, and advertising law.

Aaron heads the trademarks, copyrights, and advertising practice focusing on the areas of trademark, advertising, unfair competition, copyright, internet, retail, and consumer law.

Maya focuses on strategic patent counseling for healthcare and other technology-driven companies.

Andrea Linna is a partner at Wilson Sonsini Goodrich & Rosati, where she is a member of the firm’s digital health industry group and its healthcare practice. With more than a decade dedicated to healthcare law, Andrea exclusively represents digital health and healthcare IT clients, from emerging companies to established industry players, investors, and healthcare systems. Andrea guides her clients through the patchwork of federal and state laws that apply to digital health companies, addressing issues such as corporate practice of medicine, Stark Law compliance, Anti-Kickback Statute considerations, fee splitting, billing Medicare and Medicaid, contracting with commercial payors, value-based care arrangements, artificial intelligence, remote patient monitoring, online prescribing, scope of practice, and licensing requirements.

Jason represents companies at all stages of their life cycle, from start-ups to public companies.

Lang represents public and private companies, investment banks and venture capital firms.

Alex focuses on representing clients in the biotechnology, pharmaceutical, medical device, diagnostic, and digital health industries.

Philip focuses primarily on the representation of medical device, biotechnology, pharmaceutical, diagnostic, and digital health companies in corporate governance, IPO, M&A, public company reporting, and private equity and debt financing matters.

Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.

Ali counsels clients on patent strategy, prosecution, and diligence for financings, M&A, and IPOs.

Matt is primary outside IP counsel to more than 50 life sciences companies in Southern California.

Tracy Shapiro is a partner in Wilson Sonsini’s San Francisco office, where she advises on privacy, data security, and advertising issues, and defends clients in investigations and enforcement actions brought by the Federal Trade Commission (FTC), state attorneys general, Senate and House congressional committees, and self-regulatory bodies.